» Articles » PMID: 30211778

Early and Highly Suppressive Antiretroviral Therapy Are Main Factors Associated With Low Viral Reservoir in European Perinatally HIV-Infected Children

Abstract

Background: Future strategies aiming to achieve HIV-1 remission are likely to target individuals with small reservoir size.

Setting: We retrospectively investigated factors associated with HIV-1 DNA levels in European, perinatally HIV-infected children starting antiretroviral therapy (ART) <6 months of age.

Methods: Total HIV-1 DNA was measured from 51 long-term suppressed children aged 6.3 years (median) after initial viral suppression. Factors associated with log10 total HIV-1 DNA were analyzed using linear regression.

Results: At ART initiation, children were aged median [IQR] 2.3 [1.2-4.1] months, CD4% 37 [24-45] %, CD8% 28 [18-36] %, log10 plasma viral load (VL) 5.4 [4.4-5.9] copies per milliliter. Time to viral suppression was 7.98 [4.6-19.3] months. After suppression, 13 (25%) children had suboptimal response [≥2 consecutive VL 50-400 followed by VL <50] and/or experienced periods of virological failure [≥2 consecutive VL ≥400 followed by VL <50]. Median total HIV-1 DNA was 43 [6195] copies/10 PBMC. Younger age at therapy initiation was associated with lower total HIV-1 DNA (adjusted coefficient [AC] 0.12 per month older, P = 0.0091), with a month increase in age at ART start being associated with a 13% increase in HIV DNA. Similarly, a higher proportion of time spent virally suppressed (AC 0.10 per 10% higher, P = 0.0022) and the absence of viral failure/suboptimal response (AC 0.34 for those with fail/suboptimal response, P = 0.0483) were associated with lower total HIV-1 DNA.

Conclusions: Early ART initiation and a higher proportion of time suppressed are linked with lower total HIV-1 DNA. Early ART start and improving adherence in perinatally HIV-1-infected children minimize the size of viral reservoir.

Citing Articles

Observational study of effects of HIV acquisition and antiretroviral treatment on biomarkers of systemic immune activation.

Kosmider E, Wallner J, Gervassi A, Bender Ignacio R, Pinto-Santini D, Gornalusse G PLoS One. 2024; 19(7):e0288895.

PMID: 38976697 PMC: 11230552. DOI: 10.1371/journal.pone.0288895.


Low unspliced cell-associated HIV RNA in early treated adolescents living with HIV on long suppressive ART.

Gartner K, Dominguez-Rodriguez S, Heaney J, Gkouleli T, Grant P, Dorgham K Front Immunol. 2024; 15:1334236.

PMID: 38444847 PMC: 10912947. DOI: 10.3389/fimmu.2024.1334236.


Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission.

Bekka S, Kelly K, Haaren M, Dhummakupt A, Persaud D Curr Opin HIV AIDS. 2024; 19(2):79-86.

PMID: 38169427 PMC: 11715321. DOI: 10.1097/COH.0000000000000839.


Effective early antiretroviral therapy in perinatal-HIV infection reduces subsequent plasma inflammatory profile.

Nguyen A, Plotkin A, Odumade O, de Armas L, Pahwa S, Morrocchi E Pediatr Res. 2023; 94(5):1667-1674.

PMID: 37308683 DOI: 10.1038/s41390-023-02669-0.


Determinants of nonsuppression of HIV viral load among children receiving antiretroviral therapy in the Simiyu region: a cross-sectional study.

Mageda K, Kulemba K, Olomi W, Kapologwe N, Katalambula L, Petrucka P AIDS Res Ther. 2023; 20(1):22.

PMID: 37055786 PMC: 10099818. DOI: 10.1186/s12981-023-00515-1.


References
1.
Zanchetta M, Anselmi A, Vendrame D, Rampon O, Giaquinto C, Mazza A . Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther. 2008; 13(1):47-55. View

2.
Shiau S, Abrams E, Arpadi S, Kuhn L . Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?. Lancet HIV. 2018; 5(5):e250-e258. PMC: 7487171. DOI: 10.1016/S2352-3018(18)30012-2. View

3.
Kuhn L, Paximadis M, Dias B, Loubser S, Strehlau R, Patel F . Age at antiretroviral therapy initiation and cell-associated HIV-1 DNA levels in HIV-1-infected children. PLoS One. 2018; 13(4):e0195514. PMC: 5896970. DOI: 10.1371/journal.pone.0195514. View

4.
McManus M, Mick E, Hudson R, Mofenson L, Sullivan J, Somasundaran M . Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. PLoS One. 2016; 11(4):e0154391. PMC: 4841514. DOI: 10.1371/journal.pone.0154391. View

5.
Palma P, Romiti M, Montesano C, Santilli V, Mora N, Aquilani A . Therapeutic DNA vaccination of vertically HIV-infected children: report of the first pediatric randomised trial (PEDVAC). PLoS One. 2013; 8(11):e79957. PMC: 3842924. DOI: 10.1371/journal.pone.0079957. View